Graig Suvannavejh
Stock Analyst at Mizuho
(2.40)
# 2,426
Out of 4,944 analysts
157
Total ratings
45.83%
Success rate
-2.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Outperform | $130 → $165 | $122.87 | +34.29% | 11 | Aug 13, 2025 | |
| ALEC Alector | Upgrades: Outperform | $2.5 → $3.5 | $2.18 | +60.55% | 5 | Jul 28, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Outperform | $4 → $5 | $1.56 | +221.54% | 2 | Jul 16, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Outperform | $16 → $12 | $2.66 | +351.13% | 5 | Jun 26, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | $1.5 → $0.5 | $0.08 | +539.39% | 3 | Jun 26, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $8 → $10 | $3.22 | +210.56% | 2 | Jun 18, 2025 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $12 → $11 | $5.00 | +120.00% | 3 | May 20, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $30 → $26 | $11.01 | +136.15% | 5 | May 16, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $44 → $48 | $36.67 | +30.90% | 18 | May 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $30 → $20 | $26.58 | -24.76% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $8.30 | -3.61% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $33.00 | - | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $212 → $216 | $109.39 | +97.46% | 21 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.84 | +313.04% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $9.59 | +671.64% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $0.5 | $0.39 | +28.21% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $65.13 | -24.77% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $24.42 | +104.75% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $6.10 | +162.30% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $6.49 | +54.08% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $5.60 | +1,042.86% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $3.47 | -71.18% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $97.86 | -64.23% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $8.62 | -7.19% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $36.88 | +54.56% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $27.87 | -82.06% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $11.16 | +204.66% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $5.45 | +413.76% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $13.73 | +125.78% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $2.02 | +840.59% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $2.21 | +114.93% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $15.63 | +130.33% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $32.31 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.91 | +3,979.38% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $117.12 | +9.29% | 1 | Sep 14, 2020 |
Insmed
Aug 13, 2025
Maintains: Outperform
Price Target: $130 → $165
Current: $122.87
Upside: +34.29%
Alector
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.18
Upside: +60.55%
Neumora Therapeutics
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.56
Upside: +221.54%
Adverum Biotechnologies
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $2.66
Upside: +351.13%
Adaptimmune Therapeutics
Jun 26, 2025
Downgrades: Neutral
Price Target: $1.5 → $0.5
Current: $0.08
Upside: +539.39%
Immuneering
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $3.22
Upside: +210.56%
Corvus Pharmaceuticals
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $5.00
Upside: +120.00%
EyePoint Pharmaceuticals
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $11.01
Upside: +136.15%
Harmony Biosciences Holdings
May 15, 2025
Maintains: Outperform
Price Target: $44 → $48
Current: $36.67
Upside: +30.90%
Apellis Pharmaceuticals
May 14, 2025
Maintains: Neutral
Price Target: $30 → $20
Current: $26.58
Upside: -24.76%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $8.30
Upside: -3.61%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $33.00
Upside: -
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $109.39
Upside: +97.46%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.84
Upside: +313.04%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $9.59
Upside: +671.64%
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.39
Upside: +28.21%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $65.13
Upside: -24.77%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $24.42
Upside: +104.75%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $6.10
Upside: +162.30%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $6.49
Upside: +54.08%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $5.60
Upside: +1,042.86%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $3.47
Upside: -71.18%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $97.86
Upside: -64.23%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $8.62
Upside: -7.19%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $36.88
Upside: +54.56%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $27.87
Upside: -82.06%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $11.16
Upside: +204.66%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $5.45
Upside: +413.76%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $13.73
Upside: +125.78%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $2.02
Upside: +840.59%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $2.21
Upside: +114.93%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $15.63
Upside: +130.33%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $32.31
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.91
Upside: +3,979.38%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $117.12
Upside: +9.29%